KR102538827B1 - 항-ｖｅｇｆ-ａ 항체 및 이의 용도 - Google Patents

항-ｖｅｇｆ-ａ 항체 및 이의 용도 Download PDF

Info

Publication number
KR102538827B1
KR102538827B1 KR1020197007757A KR20197007757A KR102538827B1 KR 102538827 B1 KR102538827 B1 KR 102538827B1 KR 1020197007757 A KR1020197007757 A KR 1020197007757A KR 20197007757 A KR20197007757 A KR 20197007757A KR 102538827 B1 KR102538827 B1 KR 102538827B1
Authority
KR
South Korea
Prior art keywords
ser
leu
gly
thr
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197007757A
Other languages
English (en)
Korean (ko)
Other versions
KR20190040029A (ko
Inventor
칭 칭 리오우
나짜레노 디마시
카렌 코프만
핑 츠이
창슈 가오
마리오 에이 세페다
미텔만 아드리안 슈왈츠
Original Assignee
메디뮨 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메디뮨 리미티드 filed Critical 메디뮨 리미티드
Publication of KR20190040029A publication Critical patent/KR20190040029A/ko
Application granted granted Critical
Publication of KR102538827B1 publication Critical patent/KR102538827B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020197007757A 2016-08-23 2017-08-22 항-ｖｅｇｆ-ａ 항체 및 이의 용도 Active KR102538827B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662378391P 2016-08-23 2016-08-23
US62/378,391 2016-08-23
PCT/EP2017/071106 WO2018037001A1 (en) 2016-08-23 2017-08-22 Anti-vegf-a antibodies and uses thereof

Publications (2)

Publication Number Publication Date
KR20190040029A KR20190040029A (ko) 2019-04-16
KR102538827B1 true KR102538827B1 (ko) 2023-05-31

Family

ID=59677248

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197007757A Active KR102538827B1 (ko) 2016-08-23 2017-08-22 항-ｖｅｇｆ-ａ 항체 및 이의 용도

Country Status (9)

Country Link
US (2) US10919958B2 (https=)
EP (2) EP3783022B1 (https=)
JP (2) JP6949106B2 (https=)
KR (1) KR102538827B1 (https=)
CN (1) CN109863172B (https=)
AU (2) AU2017315076B2 (https=)
ES (1) ES2836286T3 (https=)
IL (1) IL264961B2 (https=)
WO (1) WO2018037001A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7485273B2 (ja) * 2020-06-25 2024-05-16 国立大学法人 鹿児島大学 抗ｖｅｇｆ－ａ抗体による癌に対する治療応答性を予測又は決定するための方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011518546A (ja) 2008-03-27 2011-06-30 ザイモジェネティクス， インコーポレイテッド ＰＤＧＦＲβおよびＶＥＧＦ−Ａを阻害するための組成物および方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5981216A (en) 1985-04-01 1999-11-09 Alusuisse Holdings A.G. Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
KR100816621B1 (ko) * 1997-04-07 2008-03-24 제넨테크, 인크. 항-ｖｅｇｆ 항체
PT971959E (pt) * 1997-04-07 2006-05-31 Genentech Inc Anticorpos humanizados e metodos para formar anticorpos humanizados
ES2252261T3 (es) 2000-06-28 2006-05-16 Glycofi, Inc. Metodos para producir glicoproteinas modificadas.
JP2009526520A (ja) 2006-01-17 2009-07-23 バイオレックス セラピュティックス インク 植物中でのｎ−グリカンのヒト化及び最適化のための組成物及び方法
JP2010507594A (ja) * 2006-10-20 2010-03-11 シェーリング コーポレイション 完全ヒト抗ｖｅｇｆ抗体および使用方法
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
WO2010124009A2 (en) * 2009-04-21 2010-10-28 Schering Corporation Fully human anti-vegf antibodies and methods of using
CN102276722B (zh) * 2011-01-14 2013-05-08 中国科学院北京基因组研究所 新型血管内皮生长因子人源化单克隆抗体
US9527925B2 (en) * 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US9580509B2 (en) * 2011-11-07 2017-02-28 Medimmune, Llc Multispecific and multivalent binding proteins and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011518546A (ja) 2008-03-27 2011-06-30 ザイモジェネティクス， インコーポレイテッド ＰＤＧＦＲβおよびＶＥＧＦ−Ａを阻害するための組成物および方法

Also Published As

Publication number Publication date
IL264961B2 (en) 2025-02-01
CN109863172B (zh) 2022-08-26
JP2019528074A (ja) 2019-10-10
AU2017315076B2 (en) 2020-10-08
IL264961A (https=) 2019-04-30
EP3783022A2 (en) 2021-02-24
EP3504236B1 (en) 2020-09-23
US10919958B2 (en) 2021-02-16
AU2020289850B2 (en) 2024-06-06
CA3034576A1 (en) 2018-03-01
WO2018037001A1 (en) 2018-03-01
AU2020289850A1 (en) 2021-01-28
AU2017315076A1 (en) 2019-04-04
US20210147531A1 (en) 2021-05-20
US11634483B2 (en) 2023-04-25
JP2022008447A (ja) 2022-01-13
IL264961B1 (en) 2024-10-01
JP6949106B2 (ja) 2021-10-13
EP3504236A1 (en) 2019-07-03
CN109863172A (zh) 2019-06-07
US20190202903A1 (en) 2019-07-04
JP7277531B2 (ja) 2023-05-19
EP3783022B1 (en) 2026-03-04
KR20190040029A (ko) 2019-04-16
EP3783022A3 (en) 2021-06-30
ES2836286T3 (es) 2021-06-24

Similar Documents

Publication Publication Date Title
KR102543878B1 (ko) 항-ｖｅｇｆ-ａ 및 항-ａｎｇ2 항체 및 이의 용도
KR102352670B1 (ko) 항-N3pGlu 아밀로이드 베타 펩티드 항체 및 그의 용도
CN100455598C (zh) 功能人源化抗人cd20抗体及其应用
KR20200023439A (ko) 항-cd137 항체
CN104640879A (zh) Il-18结合分子
KR20090114364A (ko) 인간 거대세포바이러스(에이치씨엠브이)에 대한 항체
KR20200047606A (ko) Il-6r 항체와 이의 항원 결합 단편 및 의학적 용도
KR102131898B1 (ko) Scf 및 갈렉틴-1을 표적으로 하는 이중표적항체 및 그 용도
AU2020289850B2 (en) Anti-vegf-a antibodies and uses thereof
CN111320687B (zh) 抗h7n9全人源单克隆抗体4e18及其制备方法与应用
KR20240009488A (ko) 에피레귤린을 표적화하는 화합물 및 방법
CA3034576C (en) Anti-vegf-a antibodies and uses thereof
HK40047851A (en) Anti-vegf-a antibodies and uses thereof
TWI795872B (zh) 抗gm2ap抗體及其應用
HK40010498B (en) Anti-vegf-a antibodies and uses thereof
HK40010498A (en) Anti-vegf-a antibodies and uses thereof
HK40008333B (en) Anti-vegf-a antibodies and uses thereof
HK40008333A (en) Anti-vegf-a antibodies and uses thereof
HK1153502A1 (en) Anti-bst2 antibody

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

N231 Notification of change of applicant
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4